Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

Webcast - update from the ODAC meeting

September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.

Investors, analysts and media were invited to listen to a webcast presentation and participate in a following Q&A session on September 26, at 14:00 (CET). The webcast was recorded.

Link to the webcast and phone numbers

Press release -

Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)

Read press release
Upcoming events

Upcoming events

View calendar

Media and Investor Relations contacts

Rolf Gulliksen

Rolf Gulliksen

Global Head of Corporate Communications

Link to Sep 22 ODAC meeting and Briefing Book

The US Food and Drug Administration (FDA) has published the Briefing Book for the Oncologic Drugs Advisory Committee (ODAC) meeting on September 22, 2022. The purpose of the meeting is to obtain the advisory committee's input regarding the benefit/risk of Pepaxto® (melphalan flufenamide, also called melflufen) for the currently indicated patient population.

Link to the Briefing Book

Link to the public ODAC meeting (starts 19:50 CET, Sep 22)

Read the press release about the Briefing Book

Jakob Lindberg

European Commission approves Oncopeptides' Pepaxti

“The approval of Pepaxti in Europe is foundational for Oncopeptides, and brings excellent news for patients and shareholders,” says Jakob. “Despite the introduction of novel therapies, patients with triple class refractory disease have a high unmet medical need, since their treatment options ultimately become exhausted.”

Link to the press release

Released

Interim report Q2 2022

EMA's recommendation to approve Pepaxti in EU is foundational for Oncopeptides

CEO Jakob Lindberg

 

See the Webcast                     


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

 

Q3 report November 9, 2022

Profile image

Presentation of the Q2 Interim Report 2022

Oncopeptides published its report for the second quarter 2022 on August 11, 2022, and hosted a webcast on the same day at 14:00 CET. The event was hosted by CEO, Jakob Lindberg, together with CMO Klaas Bakker and CFO Annika Muskantor. The presentation was held in English and was recorded.

Link to the webcast and more information

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU. 

Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor. 

More info, presentation and the webcast link

Presentation of the Q1 Report 2022

Oncopeptides published its report for the first quarter 2022 on May 4, 2022, and hosted a webcast on the same day at 11:00 CET. The event was hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation was held in English.

Link to the webcast and more information

Released

Annual Report 2021

Letter from the CEO - Science is leading the way

 

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image
Jakob Lindberg, CEO

Letter from the CEO - Science is leading the way

"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.

Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).

The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.

More info, dial in numbers and the webcast link

Jakob interviewed by Di.TV - as new CEO about going forward

In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.

See the interview (Swedish) or read the transcript

Jakob Lindberg, CEO

Jakob Lindberg appointed CEO

On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.

Read the press release

Webcast - Oncopeptides withdraw Pepaxto in US, scale down organization and focus on R&D

October 22, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.

Investors, financial analysts, and media were invited to participate in a webcast including a Q&A the same day.

The event was hosted by CEO Marty J Duvall, CMO Klaas Bakker and CSO Jakob Lindberg. The presentation was held in English and was recorded.

More info, presentation and the webcast link

CEO Marty J Duvall summurizes the Year 2020

Our vision is to bring hope to In brief patients through passionate people, innovative science, and transformative medicines.

Presentations, webcasts and transcripts

See our latest Investor presentations, webcast, transcripts and interviews

To the archive

Webcast - presentation of OCEAN data presented at IMW

Oncopeptides presented data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media were invited to participate in a webcast including a Q&A on September 12 at 16:00 CEST.

The event was hosted by Marty J Duvall, CEO, Klaas Bakker, CMO as well as Fredrik Schjesvold, MD, Head of Oslo Myeloma Center. The presentation was held in English and was recorded.

More info, presentation and the webcast link

Released

Annual Report 2020

Annual Report 2020 - online version

 

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image

Oncopeptides via e-mail

Get our latest updates straight to your inbox. Unsubscribe at anytime.

This site is protected by reCAPTCHA & the Google Privacy Policy & Terms of Service  apply.